Unknown

Dataset Information

0

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.

ABSTRACT:

SUBMITTER: Venugopal S 

PROVIDER: S-EPMC8237705 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
| S-EPMC8045494 | biostudies-literature
Unknown Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
| S-EPMC6318429 | biostudies-literature
Unknown Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
| S-EPMC8116235 | biostudies-literature
Unknown Combined venetoclax and alvocidib in acute myeloid leukemia.
| S-EPMC5739808 | biostudies-other
Unknown Venetoclax-based therapies for acute myeloid leukemia.
| S-EPMC6581210 | biostudies-literature
Unknown Venetoclax-containing regimens in acute myeloid leukemia.
| S-EPMC7882757 | biostudies-literature
Unknown IDH1/IDH2 Inhibition in Acute Myeloid Leukemia.
| S-EPMC8063727 | biostudies-literature
Unknown Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
| S-EPMC3888021 | biostudies-other
Unknown Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
| S-EPMC6606342 | biostudies-literature
Unknown TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
| S-EPMC5217532 | biostudies-literature